Robert Wood Johnson Foundation Clinical Scholars, University of Michigan, Ann Arbor, Michigan, USA.
Oncologist. 2013;18(5):584-91. doi: 10.1634/theoncologist.2012-0415. Epub 2013 May 1.
It is unknown whether changes in study sponsorship have affected the proportion of prospective research on surgery, radiotherapy, and pharmacotherapy for head and neck squamous cell carcinoma (HNSCC) being published over time.
We examined prospective studies from PubMed, Ovid MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1980, 1985, 1990, 1995, 2000, 2005, and 2010. Chi-squared tests were used to identify significant associations between sponsorship and authorship, treatments within study protocols, and presentation of results, whereas time-based trends were analyzed using the Cochran-Armitage test.
Among 309 articles, industry (70, 22.7%) and the U.S. government (65, 21%) were the most common sponsors. There was a significant increase in the proportion of industry-sponsored research (p for trend = .013) and a decline in U.S. government-sponsored research (p for trend = .001) over time. The inclusion of surgery in treatment protocols declined over the past four decades (p for trend = .003). Protocols incorporating pharmacotherapy were more likely to have industry support than those without pharmacotherapy (p = .001), whereas protocols with radiotherapy (p = .003) or surgery (p = .002) were less likely to have industry support.
Industry is the predominant sponsor of prospective HNSCC research, with an emphasis on pharmacotherapy.
目前尚不清楚研究资助的变化是否会影响头颈部鳞状细胞癌（HNSCC）前瞻性研究中关于手术、放疗和药物治疗的比例随时间的变化。
我们从 1980 年、1985 年、1990 年、1995 年、2000 年、2005 年和 2010 年的 PubMed、Ovid MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库中检查了前瞻性研究。采用卡方检验来确定资助与作者、研究方案内治疗方法以及结果呈现之间的显著关联，而时间趋势则采用 Cochran-Armitage 检验进行分析。
在 309 篇文章中，工业界（70 篇，22.7%）和美国政府（65 篇，21%）是最常见的资助者。工业资助的研究比例显著增加（趋势检验 p 值=0.013），而美国政府资助的研究比例则随时间下降（趋势检验 p 值=0.001）。在过去的四十年中，治疗方案中纳入手术的比例有所下降（趋势检验 p 值=0.003）。包含药物治疗的方案比不包含药物治疗的方案更有可能获得工业支持（p=0.001），而包含放疗（p=0.003）或手术（p=0.002）的方案则不太可能获得工业支持。
工业界是 HNSCC 前瞻性研究的主要资助者，重点是药物治疗。
